Cover Image
Market Research Report
Product code 

Subcutaneous Self Injection Markets to 2026

Published: | Greystone Research Associates | Delivery time: 1-2 business days


Back to Top
Subcutaneous Self Injection Markets to 2026
Published: November 30, 2019
Greystone Research Associates
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents

A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application. As these combination products have proliferated, so too have product strategies. Several pharma and biotech companies are embracing the combination product concept and using it to differentiate their drug offerings, while others are opting for a minimalist approach. Interferons for treating Multiple Sclerosis are primarily marketed in prefilled syringes, while human growth hormone indicated for hormone deficiency in children is supplied almost exclusively in reusable, custom-designed variable dose pen injectors. Even within a particular therapeutic drug class, strategic variations are evident.

Subcutaneous Self Injection Markets to 2026 - What You Will Learn

  • Provides detailed analysis of self-administered subcutaneous drug products, drug delivery and device strategies, and product development factors
  • Assesses key markets, market dynamics and market demographics
  • Analyzes therapeutic demand drivers and evaluates SC drug products in nine key therapeutic segments
  • Provides market data and forecasts to 2026
  • Profiles market sector participants, their product development activities, business strategies, and corporate alliances and affiliations
  • Assesses the importance of alliances and partnerships on self-administered subcutaneous drug product commercialization
  • Evaluates the impact of economic, technology, and regulatory factor
Table of Contents
Product Code: SSJ4X9

Table of Contents

Subcutaneous Self Injection Markets to 2026 - Summary of Contents

  • Executive Summary
  • The Market Opportunity
  • Subcutaneous Self-Administration - Why it's Growing
  • The Evolving Drug Pipeline
  • Device and Packaging Technology Advances
  • Shifting Patient Demographics
  • Healthcare Economics
  • Demand Drivers
  • Innovation in Prefilled Device Designs
  • Therapeutic Targets and Treatment
  • Competitive Landscape
  • Risk Factors
  • Subcutaneous Delivery Device Design Factors
  • Ergonomics and Ease of Use
  • Safety Features
  • Lyophilized Drugs/Reconstitution
  • High Viscosity Drugs
  • High Volume Drugs
  • Subcutaneously Delivered Drugs - Device Strategies
  • Handheld Devices
  • Prefilled Syringes
  • Autoinjectors
  • Pen Injectors
  • Dual Chamber Pens
  • Emerging Devices
  • Other Handheld Devices
  • Needle-free Injectors
  • Wearable Devices
  • Patch Pumps
  • Large Volume Wearable Devices
  • Subcutaneous Self-Administration
  • Therapeutic Sector Product Analysis & Forecasts
  • Anticoagulants
  • Antivirals
  • Autoimmune Diseases
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Juvenile Ideopathic Arthritis
  • Ankylosing Spondylitis
  • Crohn's Disease
  • Autoimmune Anti-Inflammatory SC Therapeutics
  • Interleukin Receptor Agonists
  • TNF Inhibitors
  • Multiple Sclerosis
  • Diabetes
  • Insulin
  • Type 2 Glycemic control
  • Hematopoietics
  • Hormone Replacement
  • Neurology
  • Osteoporosis
  • Reproductive Health
  • Market Factors
  • Regulatory Issues
  • DTC Marketing
  • Market Sector Participant Profiles